Mannkind to Manufacture 12-unit Cartridge Strength of Afrezza®

MannKind Corp. (NASDAQ:MNKD) announced plans to start manufacturing a 12-unit cartridge strength of Afrezza® Inhalation Powder. The new cartridge was approved by the US Food and Drug Administration earlier this month, and launch is expected in the second half of 2015.

About Afrezza®:

Afrezza^® (insulin human) Inhalation Powder is used to control high blood sugar in adults with type 1 and type 2 diabetes. The drug-device combination product consists of a dry formulation of human insulin delivered in a specially designed inhaler. Administered at the beginning of a meal, Afrezza^® delivers insulin into the body through the lungs with peak insulin levels achieved within 12 to 15 minutes. Afrezza^® is available in 4-unit and 8-unit single-use cartridges that can be combined to meet the prescribed dose. In addition, the U.S. Food and Drug Administration (FDA) recently approved a 12-unit cartridge strength of insulin powder for Afrezza^®. The disposable inhaler can be used to take the cartridges for up to 15 days and does not require cleaning or maintenance.

Sanofi and MannKind have entered into a worldwide exclusive licensing agreement to develop and commercialize Afrezza^®. Under the collaboration agreement, Sanofi is responsible for global commercial, regulatory and development activities.

Click here to read the full Mannkind Corp. (NASDAQ:MNKD) press release.

MannKind Corporation (Nasdaq:MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at https://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on theMannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with theSecurities and Exchange Commission or posts certain other information to the website.